LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Ventyx Biosciences Inc

Suletud

2.45 8.89

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.22

Max

2.46

Põhinäitajad

By Trading Economics

Sissetulek

1.9M

-27M

Aktsiakasum

-0.39

Töötajad

81

EBITDA

2.4M

-30M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+677.78% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. aug 2025

Turustatistika

By TradingEconomics

Turukapital

42M

145M

Eelmine avamishind

-6.44

Eelmine sulgemishind

2.45

Ventyx Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. sept 2024, 12:43 UTC

Suurimad hinnamuutused turgudel

Ventyx Biosciences Shares Rise Premarket on Sanofi Investment

Võrdlus sarnastega

Hinnamuutus

Ventyx Biosciences Inc Prognoos

Hinnasiht

By TipRanks

677.78% tõus

12 kuu keskmine prognoos

Keskmine 17.5 USD  677.78%

Kõrge 21 USD

Madal 14 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Ventyx Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

3

Osta

2

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.